#Astellas bietet 5,9 Mrd. #Dollar für Biotechfirma Iveric
https://www.boersen-zeitung.de/unternehmen-branchen/astellas-bietet-59-mrd-dollar-fuer-biotechfirma-iveric?utm_campaign=mastodon&utm_source=mastodon&utm_medium=Digital
Astellas to acquire eye drug developer Iveric Bio for $5.9B —With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer—Otsuka, Lundbeck gain FDA nod for longer-acting version of schizophrenia drug Abilify -- See more on our front page news http://bit.ly/w28kSd #astellas #mergersandacquisitions #eyehealth #fda #prostatecancer #astrazeneca #abilify #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#astellas #mergersandacquisitions #eyehealth #FdA #ProstateCancer #astrazeneca #abilify #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#Menopause Mongering Returns, Big Time
by Martha Rosenberg, April 3, 2023
"Why the revival? The drug company #Astellas just received a new drug application for fezolinetant, a drug to treat '#VMS' and selling the disease to create 'demand' for a drug is a time honored drug maker tradition. It is buttressed by online 'quizzes' and 'symptom checkers' to help patients self-diagnose the sold condition and go to the doctor requesting the new drug. 'Unbranded' advertising, in which a disease rather than a drug is sold, is often mistaken for messages from the CDC by the public which helps the sell."
Read more: https://www.counterpunch.org/2023/04/03/menopause-mongering-returns-big-time/
https://www.counterpunch.org/2023/04/03/menopause-mongering-returns-big-time/
#menopause #astellas #vms #bigpharma #marketing
FDA approves Keytruda/Padcev combo in advanced urothelial cancer — Record growth in U.S. life sciences real estate footprint — Diabesity drugs and their free ‘contract sales force’ -- See more on our front page news http://bit.ly/w28kSd #fda #merck #astellas #urothelialcancer #realestate #diabetes #obesity #novonordisk #elililly #keytruda #lifesciences #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#FdA #merck #astellas #urothelialcancer #realestate #diabetes #obesity #novonordisk #elililly #keytruda #lifesciences #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
US again spurns march-in campaign to slash cost of Pfizer, Astellas' Xtandi — Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test— Boston Scientific, Medtronic expected to quickly capture new atrial fibrillation market -- See more on our front page news http://bit.ly/w28kSd #pfizer #astellas #prostatecancer #roche #elililly #diagnostics #medtech #alzheimers #atrialfibrillation #afib #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#pfizer #astellas #ProstateCancer #roche #elililly #diagnostics #medtech #alzheimers #AtrialFibrillation #afib #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Alzheimer's Association campaigns for broader Leqembi coverage — FDA reverses course; will hold adcomm for Sarepta’s DMD gene therapy— Pfizer and Astellas report positive data from prostate cancer therapy trial -- See more on our front page news http://bit.ly/w28kSd #alzheimers #eisai #biogen #fda #dmd #duchenne #pfizer #astellas #clinicaltrials #prostatecancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#alzheimers #eisai #biogen #FdA #dmd #Duchenne #pfizer #astellas #clinicaltrials #ProstateCancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Vaccines slip, Dupixent climbs for Sanofi as it readies multiple launches in 2023 — Astellas taps new CEO —Biogen and Sage get FDA priority review of depression med zuranolone -- See more on our front page news http://bit.ly/w28kSd #sanofi #earnings #druglaunches #astellas #ceos #biogen #sagetherapeutics #fda #depression #postpartumdepression #priorityreview #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
#Sanofi #earnings #druglaunches #astellas #ceos #biogen #sagetherapeutics #FdA #depression #postpartumdepression #priorityreview #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
AZ wins patent fight with Viatris, gains more exclusivity for blockbuster Symbicort — AbbVie leaves PhRMA, BIO: reports —Astellas’ Phase III gastric cancer therapy trial meets primary endpoint -- See more on our front page news http://bit.ly/w28kSd #astrazeneca #patents #Symbicort #BIO #PhRMA #abbvie #astellas #clinicaltrials #gastriccancer #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
#astrazeneca #patents #symbicort #bio #phrma #abbvie #astellas #clinicaltrials #gastriccancer #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma